Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease

SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Dinesh, Tashkin, Donald P, Denton, Christopher P, Lubell, Martin W, Vazquez-Mateo, Cristina, Wax, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434373/
https://www.ncbi.nlm.nih.gov/pubmed/29893938
http://dx.doi.org/10.1093/rheumatology/key151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434373/
https://www.ncbi.nlm.nih.gov/pubmed/29893938
http://dx.doi.org/10.1093/rheumatology/key151

Ejemplares similares